
|Videos|June 9, 2015
Expanded Access Program for Radium-223 in Prostate Cancer
Author(s)Oliver Sartor, MD
Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the United States experience of the Expanded Access Program (EAP) on radium-223 for prostate cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































